Synergy between colistin and the signal peptidase inhibitor MD3 is dependent on the mechanism of colistin resistance in Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 7, 2016, Pages 4375-4379

  Martínez Guitián, Marta ^a   Vázquez Ucha, Juan C ^a   Odingo, Joshua ^b   Parish, Tanya ^b   Poza, Margarita ^a   Waite, Richard D ^c   Bou, German ^a   Wareham, David W ^c   Beceiro, Alejandro ^a  

^a Biobanco A Coruña Instituto de Investigación Biomédica de A Coruña INIBIC   (Spain)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,5 DICHLOROPHENYL) 3 (DIMETHYLAMINO)PROPAN 1 ONE; AMINO ACID; COLISTIN; LIPID A; LIPOPOLYSACCHARIDE; PHOSPHOETHANOLAMINE; PROTEINASE INHIBITOR; SIGNAL PEPTIDASE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIUM ISOLATE; CASE REPORT; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION INDEX; HUMAN; HUMAN TISSUE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; DRUG EFFECTS; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; PROTEASE INHIBITORS;

EID: 84977103509     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00510-16     Document Type: Article

References (26)

1. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538-582. http://dx.doi.org/10.1128/CMR.00058-07.
2. Huttner B, Jones M, Rubin MA, Neuhauser MM, Gundlapalli A, Samore M. 2012. Drugs of last resort? The use of polymyxins and tigecycline at US Veterans Affairs medical centers, 2005-2010. PLoS One 7:e36649.
3. Hancock RE. 1997. Peptide antibiotics. Lancet 349:418-422. http://dx.doi.org/10.1016/S0140-6736(97)80051-7.
4. Cai Y, Chai D, Wang R, Liang B, Bai N. 2012. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67:1607-1615. http://dx.doi.org/10.1093/jac/dks084.
5. Olaitan AO, Morand S, Rolain JM. 2014. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol 5:643.
6. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 54:4971-4977. http://dx.doi.org/10.1128/AAC.00834-10.
7. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, Woodford N. 2011. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 55:3370-3379. http://dx.doi.org/10.1128/AAC.00079-11.
8. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 53:3628-3634. http://dx.doi.org/10.1128/AAC.00284-09.
9. Kempf M, Rolain JM. 2012. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 39:105-114. http://dx.doi.org/10.1016/j.ijantimicag.2011.10.004.
10. Durante-Mangoni E, Utili R, Zarrilli R. 2014. Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date. Future Microbiol 9:773-789. http://dx.doi.org/10.2217/fmb.14.34.
11. Personne Y, Curtis MA, Wareham DW, Waite RD. 2014. Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin. J Antimicrob Chemother 69:3236-3243. http://dx.doi.org/10.1093/jac/dku309.
12. Paetzel M, Karla A, Strynadka NC, Dalbey RE. 2002. Signal peptidases. Chem Rev 102:4549-4580. http://dx.doi.org/10.1021/cr010166y.
13. Bou G, Oliver A, Martínez-Beltrán J. 2000. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother 44:1556-1561. http://dx.doi.org/10.1128/AAC.44.6.1556-1561.2000.
14. Pournaras S, Poulou A, Dafopoulou K, Chabane YN, Kristo I, Makris D, Hardouin J, Cosette P, Tsakris A, Dé E. 2014. Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in Acinetobacter baumannii. Antimicrob Agents Chemother 58:828-832. http://dx.doi.org/10.1128/AAC.01439-13.
15. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: 17th informational supplement M07-A9. CLSI, Wayne, PA, USA.
16. Hsieh MH, Yu CM, Yu VL, Chow JW. 1993. Synergy assessed by checkerboard. A critical analysis. Diagn Microbiol Infect Dis 16:343-349. http://dx.doi.org/10.1016/0732-8893(93)90087-N.
17. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1. http://dx.doi.org/10.1093/jac/dkg301.
18. Beceiro A, Moreno A, Fernández N, Vallejo JA, Aranda J, Adler B, Harper M, Boyce JD, Bou G. 2014. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob Agents Chemother 58:518-526. http://dx.doi.org/10.1128/AAC.01597-13.
19. Kim Y, Bae IK, Jeong SH, Yong D, Lee K. 2015. In vivo selection of pan-drug resistant Acinetobacter baumannii during antibiotic treatment. Yonsei Med J 56:928-934. http://dx.doi.org/10.3349/ymj.2015.56.4.928.
20. Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, Onmus-Leone F, Preston L, St Clair K, Nikolich M, Viscount H, Wortmann G, Zapor M, Grillot-Courvalin C, Courvalin P, Clifford R, Waterman PE. 2013. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis 208:1142-1151. http://dx.doi.org/10.1093/infdis/jit293.
21. Mavroidi A, Likousi S, Palla E, Katsiari M, Roussou Z, Maguina A, Platsouka ED. 2015. Molecular identification of tigecycline- and colistin-resistant carbapenemase-producing Acinetobacter baumannii from a Greek hospital from 2011 to 2013. J Med Microbiol 64:993-997. http://dx.doi.org/10.1099/jmm.0.000127.
22. Durante-Mangoni E, Del Franco M, Andini R, Bernardo M, Giannouli M, Zarrilli R. 2015. Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 82:222-226. http://dx.doi.org/10.1016/j.diagmicrobio.2015.03.013.
23. Selasi GN, Nicholas A, Jeon H, Lee YC, Yoo JR, Heo ST, Lee JC. 2015. Genetic basis of antimicrobial resistance and clonal dynamics of carbapenem-resistant Acinetobacter baumannii sequence type 191 in a Korean hospital. Infect Genet Evol 36:1-7. http://dx.doi.org/10.1016/j.meegid.2015.09.001.
24. Soon RL, Nation RL, Cockram S, Moffatt JH, Harper M, Adler B, Boyce JD, Larson I, Li J. 2011. Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment. J Antimicrob Chemother 66:126-133. http://dx.doi.org/10.1093/jac/dkq422.
25. Wand ME, Bock LJ, Bonney LC, Sutton JM. 2015. Retention of virulence following adaptation to colistin in Acinetobacter baumannii reflects the mechanism of resistance. J Antimicrob Chemother 70:2209-2216. http://dx.doi.org/10.1093/jac/dkv097.
26. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16:161-168. http://dx.doi.org/10.1016/S1473-3099(15)00424-7.